Impact of CYP3A4*1G Polymorphism on Metabolism of Fentanyl in Chinese Patients Undergoing Lower Abdominal Surgery
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01181492 |
Recruitment Status :
Completed
First Posted : August 13, 2010
Results First Posted : November 1, 2013
Last Update Posted : November 1, 2013
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Condition or disease |
---|
Pain Surgery |
Study Type : | Observational |
Actual Enrollment : | 176 participants |
Official Title: | Impact of CYP3A4*1G Polymorphism on Metabolism of Fentanyl in Chinese Patients Undergoing Lower Abdominal Surgery |
Study Start Date : | November 2008 |
Actual Primary Completion Date : | April 2010 |
Actual Study Completion Date : | April 2010 |
Group/Cohort |
---|
*1/*1
Grouped by CYP3A4*1G polymorphism, wild-type homozygote
|
*1/*1G
Grouped by CYP3A4*1G polymorphism,*1/*1G: mutant heterozygote
|
*1G/*1G
Grouped by CYP3A4*1G polymorphism,*1G/*1G: mutant homozygote
|
- CYP3A4*1G Polymorphism [ Time Frame: 48 hours after operation ]According to CYP3A4*1G polymorphism,patients are devided into three groups: *1/*1,*1/*1G,*1G/*1G
- The Visual Analog Scale 24 Hours Postoperative [ Time Frame: 24 hours after operation ]The visual analog scale (VAS) is used for pain evaluation at rest which from 0 to 10 (higher values represent morepain) during patient-controlled analgesia (PCA) treatment 24 h after operation
- PCA Fentanyl Consumption [ Time Frame: 24 h after surgery ]PCA fentanyl consumption and adverse effects are recorded during the first 24 h after surgery.
Biospecimen Retention: Samples With DNA

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 20 Years to 65 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
- Aged 20-65 years
- Anesthesiologists (ASA) physical status I or II;
- With ±20% of ideal body weight;
- Received PCA administration;
- Agreed to participate the research
Exclusion Criteria:
- History of chronic pain;
- Psychiatric diseases;
- Diabetes mellitus;
- Severe cardiovascular diseases;
- Kidney or liver diseases;
- Alcohol or drug abuse (according to the criteria of DSM-IV);
- Pregnancy or at lactation period;
- Consumed drugs (1week) or foods (3 days) known to inhibit or induce the expression of CYP3A4 enzymes prior to surgery;
- Refused PCA administration;
- Disagree to participate to the research

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01181492
China, Hubei | |
1. Department of Anesthesiology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology | |
Wuhan,, Hubei, China, 430030 |
Study Director: | Zhang Xianwei, MD | Huazhong University of Science and Technology |
Responsible Party: | Xianwei Zhang, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology |
ClinicalTrials.gov Identifier: | NCT01181492 |
Other Study ID Numbers: |
HuazhongU |
First Posted: | August 13, 2010 Key Record Dates |
Results First Posted: | November 1, 2013 |
Last Update Posted: | November 1, 2013 |
Last Verified: | August 2013 |
gene polymorphism CYP3A4 fentanyl HPLC Analgesics |